应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
HOTH Hoth Therapeutics
交易中 03-03 10:12:43 EST
0.9883
-0.0317
-3.11%
最高
1.01
最低
0.9851
成交量
1.16万
今开
1.01
昨收
1.02
日振幅
2.44%
总市值
1,533万
流通市值
1,479万
总股本
1,551万
成交额
1.16万
换手率
0.08%
流通股本
1,496万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Hoth Therapeutics公司公布Cleer-001中期数据：队列患者100%达到主要疗效终点
美股速递 · 02-25
Hoth Therapeutics公司公布Cleer-001中期数据：队列患者100%达到主要疗效终点
Hoth Therapeutics 因患者需求增加，增设新临床中心加速 HT-001 试验入组
美股速递 · 02-25
Hoth Therapeutics 因患者需求增加，增设新临床中心加速 HT-001 试验入组
Hoth Therapeutics：GDNF疗法使体重增长减缓10-15%，治疗末期趋于稳定
美股速递 · 02-10
Hoth Therapeutics：GDNF疗法使体重增长减缓10-15%，治疗末期趋于稳定
Hoth Therapeutics：匈牙利、西班牙及波兰的国别第二部分监管决定预计于2026年1月19日前公布
美股速递 · 01-15
Hoth Therapeutics：匈牙利、西班牙及波兰的国别第二部分监管决定预计于2026年1月19日前公布
Hoth Therapeutics 迎来欧盟关键监管节点，推动HT-001肿瘤试验在多国启动临床中心
美股速递 · 01-15
Hoth Therapeutics 迎来欧盟关键监管节点，推动HT-001肿瘤试验在多国启动临床中心
Hoth Therapeutics发布全面管线更新，强调临床进展、孤儿药Ht-Kit的推进、Ht-001第二阶段的推进及新Gdnf代谢项目
美股速递 · 2025-12-04
Hoth Therapeutics发布全面管线更新，强调临床进展、孤儿药Ht-Kit的推进、Ht-001第二阶段的推进及新Gdnf代谢项目
霍思疗法公司获准加入英伟达连接计划，扩展其人工智能和加速计算能力
美股速递 · 2025-11-20
霍思疗法公司获准加入英伟达连接计划，扩展其人工智能和加速计算能力
Hoth Therapeutics启动VA支持的研究，探讨新型GDNF减肥疗法针对肥胖和脂肪肝疾病
美股速递 · 2025-10-27
Hoth Therapeutics启动VA支持的研究，探讨新型GDNF减肥疗法针对肥胖和脂肪肝疾病
Hoth Therapeutics获得FDA孤儿药资格并为Ht-Kit在罕见C-Kit驱动癌症中的强大临床前数据进行报告
美股速递 · 2025-10-21
Hoth Therapeutics获得FDA孤儿药资格并为Ht-Kit在罕见C-Kit驱动癌症中的强大临床前数据进行报告
Hoth Therapeutics通过专利申请扩展Ht-001开发项目，针对药物过敏反应、放疗皮疹及Menin抑制剂皮肤毒性
美股速递 · 2025-09-24
Hoth Therapeutics通过专利申请扩展Ht-001开发项目，针对药物过敏反应、放疗皮疹及Menin抑制剂皮肤毒性
Hoth Therapeutics发布股东更新：Ht-001、Ht-Kit、扩大财务储备策略及VA肥胖项目推动公司达到历史最强地位
美股速递 · 2025-09-16
Hoth Therapeutics发布股东更新：Ht-001、Ht-Kit、扩大财务储备策略及VA肥胖项目推动公司达到历史最强地位
Hoth Therapeutics向EMA提交HT-001治疗EGFR抑制剂引起皮肤毒性癌症患者的II期临床试验申请，取得重要欧洲监管里程碑
美股速递 · 2025-09-10
Hoth Therapeutics向EMA提交HT-001治疗EGFR抑制剂引起皮肤毒性癌症患者的II期临床试验申请，取得重要欧洲监管里程碑
Hoth Therapeutics, Inc.盘中异动 股价大跌5.50%
市场透视 · 2025-03-10
Hoth Therapeutics, Inc.盘中异动 股价大跌5.50%
Hoth Therapeutics, Inc.盘中异动 早盘股价大跌5.65%
市场透视 · 2025-03-05
Hoth Therapeutics, Inc.盘中异动 早盘股价大跌5.65%
Hoth Therapeutics, Inc.盘中异动 股价大涨5.24%报1.59美元
市场透视 · 2025-01-16
Hoth Therapeutics, Inc.盘中异动 股价大涨5.24%报1.59美元
Hoth Therapeutics, Inc.盘中异动 大幅上涨6.13%报1.65美元
市场透视 · 2025-01-15
Hoth Therapeutics, Inc.盘中异动 大幅上涨6.13%报1.65美元
D. Boral Capital：维持Hoth Therapeutics(HOTH.US)评级，由买入调整至买入评级, 目标价由5.00美元调整至5.00美元。
金融界 · 2025-01-08
D. Boral Capital：维持Hoth Therapeutics(HOTH.US)评级，由买入调整至买入评级, 目标价由5.00美元调整至5.00美元。
Hoth Therapeutics, Inc.股价飙升100.71% 市值涨1143.76万美元
市场透视 · 2025-01-07
Hoth Therapeutics, Inc.股价飙升100.71% 市值涨1143.76万美元
Hoth Therapeutics, Inc.盘中异动 早盘股价大跌5.13%
市场透视 · 2024-11-25
Hoth Therapeutics, Inc.盘中异动 早盘股价大跌5.13%
加载更多
公司概况
公司名称：
Hoth Therapeutics
所属市场：
NASDAQ
上市日期：
--
主营业务：
Hoth Therapeutics, Inc.于2017年5月16日根据内华达州法律注册成立。该公司是一家处于发展阶段的生物制药公司，专注于为患有特应性皮炎（又称湿疹）等疾病的患者提供靶向治疗。该公司的主要资产是与Chelexa的分许可协议，根据该协议，Chelexa已授予使用其BioLexa平台的独家分许可，该平台是在辛辛那提大学开发的专有、专利、药物化合物平台。该许可证允许为人类的任何适应症开发该平台。该公司最初的重点将是通过应用外用乳膏来治疗湿疹。BioLexa平台以局部剂型将FDA批准的锌螯合剂与一种或多种批准的抗生素相结合，通过防止传染性生物膜的形成以及由此引发症状的汗管堵塞，解决未经检查的湿疹发作问题。该公司是第一个旨在防止症状引发突发而不是简单地在出现症状时进行治疗的候选产品。
发行价格：
--
{"stockData":{"symbol":"HOTH","market":"US","secType":"STK","nameCN":"Hoth Therapeutics","latestPrice":0.9883,"timestamp":1772550742802,"preClose":1.02,"halted":0,"volume":11624,"delay":0,"changeRate":-0.03107843137254908,"floatShares":14960700,"shares":15514312,"eps":-1.013412,"marketStatus":"交易中","change":-0.0317,"latestTime":"03-03 10:12:43 EST","open":1.01,"high":1.01,"low":0.9851,"amount":11571.0317568,"amplitude":0.024412,"askPrice":0.9949,"askSize":2,"bidPrice":0.9851,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-1.013412,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772571600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1550206800000,"exchange":"NASDAQ","adjPreClose":1.02,"preHourTrading":{"tag":"盘前","latestPrice":0.985,"preClose":1.02,"latestTime":"08:00 EST","volume":1257,"amount":1238.1599583,"timestamp":1772542811727,"change":-0.035,"changeRate":-0.034314,"amplitude":0.014608},"postHourTrading":{"tag":"盘后","latestPrice":0.9803,"preClose":1.02,"latestTime":"19:57 EST","volume":499,"amount":504.6498,"timestamp":1772499432734,"change":-0.0397,"changeRate":-0.038922,"amplitude":0.048725},"volumeRatio":0.429647},"requestUrl":"/m/hq/s/HOTH","defaultTab":"news","newsList":[{"id":"1189620458","title":"Hoth Therapeutics公司公布Cleer-001中期数据：队列患者100%达到主要疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1189620458","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189620458?lang=zh_cn&edition=full","pubTime":"2026-02-25 05:17","pubTimestamp":1771967841,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics公司最新发布的Cleer-001中期临床试验数据显示，该研究队列中的所有患者均成功达到了预设的主要疗效终点，这一结果标志着候选疗法在目标患者群体中展现出显著的临床潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"gpt_icon":0},{"id":"1158626179","title":"Hoth Therapeutics 因患者需求增加，增设新临床中心加速 HT-001 试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1158626179","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158626179?lang=zh_cn&edition=full","pubTime":"2026-02-25 05:15","pubTimestamp":1771967741,"startTime":"0","endTime":"0","summary":"随着患者需求显著上升，Hoth Therapeutics 正通过增设新的临床研究中心，全力加快其核心候选药物 HT-001 的临床试验患者入组进程。\n这一战略举措旨在高效应对日益增长的患者参与意愿，确保试验能够按计划甚至提前推进，从而为后续的药物开发奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"gpt_icon":0},{"id":"1120538790","title":"Hoth Therapeutics：GDNF疗法使体重增长减缓10-15%，治疗末期趋于稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1120538790","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120538790?lang=zh_cn&edition=full","pubTime":"2026-02-10 21:33","pubTimestamp":1770730393,"startTime":"0","endTime":"0","summary":"生物制药公司Hoth Therapeutics宣布，其研发的GDNF疗法在实验研究中展现出显著效果——能够将体重增长幅度抑制10%至15%。值得注意的是，在治疗周期的最后几周，受试者的体重数据进入平台期，不再呈现明显上升趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"gpt_icon":0},{"id":"1175429669","title":"Hoth Therapeutics：匈牙利、西班牙及波兰的国别第二部分监管决定预计于2026年1月19日前公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1175429669","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175429669?lang=zh_cn&edition=full","pubTime":"2026-01-15 21:19","pubTimestamp":1768483154,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics公司宣布，针对其产品在匈牙利、西班牙和波兰的国别第二部分监管审批决定，预计将在2026年1月19日前作出。这一关键进展将直接影响该公司在欧洲市场的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"gpt_icon":0},{"id":"1185056438","title":"Hoth Therapeutics 迎来欧盟关键监管节点，推动HT-001肿瘤试验在多国启动临床中心","url":"https://stock-news.laohu8.com/highlight/detail?id=1185056438","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185056438?lang=zh_cn&edition=full","pubTime":"2026-01-15 21:19","pubTimestamp":1768483153,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics近日迎来其在欧盟监管流程中的关键转折点，为公司核心肿瘤疗法HT-001的临床试验铺平道路。这一进展将直接推动试验方案在多个欧洲国家启动临床研究中心，加速全球研发布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"gpt_icon":0},{"id":"1163130191","title":"Hoth Therapeutics发布全面管线更新，强调临床进展、孤儿药Ht-Kit的推进、Ht-001第二阶段的推进及新Gdnf代谢项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1163130191","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163130191?lang=zh_cn&edition=full","pubTime":"2025-12-04 03:00","pubTimestamp":1764788436,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics发布全面管线更新，强调临床进展、孤儿药Ht-Kit的推进、Ht-001第二阶段的推进及新Gdnf代谢项目","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"gpt_icon":0},{"id":"1113935998","title":"霍思疗法公司获准加入英伟达连接计划，扩展其人工智能和加速计算能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1113935998","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113935998?lang=zh_cn&edition=full","pubTime":"2025-11-20 21:13","pubTimestamp":1763644403,"startTime":"0","endTime":"0","summary":"霍思疗法公司获准加入英伟达连接计划，扩展其人工智能和加速计算能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2247934214.USD","NVD2.UK","BK4554","LU0077335932.USD","LU2108987350.USD","LU2092627202.USD","IE0004445015.USD","LU0006306889.USD","LU2237438978.USD","LU1917777945.USD","LU0345768740.USD","BK4579","LU1934455277.USD","LU2097344357.USD","LU0158827781.USD","LU0823434583.USD","LU2756315318.SGD","LU2065171402.SGD","HK0000306701.USD","LU0511384066.AUD","LU2106854487.HKD","LU0187121727.USD","SNVD.UK","LU2065171311.SGD","IE00BJTD4V19.USD","SG9999015358.SGD","LU0444971666.USD","LU1839511570.USD","LU0094547139.USD","NVDD","LU0943347566.SGD","LU2322448791.USD","LU2213496289.HKD","BK4551","LU0289960550.SGD","LU0889565833.HKD","LU1242518931.SGD","LU2471134952.CNY","LU0342679015.USD","LU1989772840.SGD","LU1935042488.USD","LU2125154778.USD","NVDL","LU0210536198.USD","LU0964807845.USD","LU1261432733.SGD","IE0034235295.USD","LU1674673428.USD","LU1989772923.USD","LU2357305700.SGD","IE00B5949003.HKD","LU0106261372.USD","BK4598","SG9999014898.SGD","LU2168564149.EUR","SG9999014906.USD","HOTH","LU0128525929.USD","LU2294711713.HKD","LU0823421333.USD","LU2360107168.USD","IE00BQXX3F31.USD","LU1127390331.HKD","LU0256863902.USD","LU0234570918.USD","LU2592432038.USD","LU1548497426.USD","LU1868837300.USD","IE00BDRTCR15.USD","LU0289961442.SGD","LU0053666078.USD","NVDU","LU2125154935.USD","LU2360106780.USD","LU1951200564.SGD","LU1868836914.USD","LU2249611893.SGD","SGXZ31699556.SGD","LU1791710582.SGD","LU0528227936.USD","IE0034235303.USD","NVD","LU0354030511.USD","SG9999017495.SGD","LU2458330243.SGD","LU1804176565.USD","BK4533","BK4007","IE00BWXC8680.SGD","LU2491050154.USD","LU0476273544.USD","LU2361044949.HKD","LU1989764748.USD","BK4614","LU0965509010.AUD","SG9999004303.SGD","LU2413666699.HKD","LU1066051225.USD","LU0070217475.USD","IE00B1BXHZ80.USD","IE00BFSS8Q28.SGD","LU0210528500.USD","LU1366192091.USD","LU2125909593.SGD","IE00BZ199S13.USD","LU0345769128.USD","LU2271345857.HKD","IE00BK4W5M84.HKD","LU2458330169.SGD","LU2931357623.SGD","LU2456880835.USD","IE00BQXX3C00.GBP","LU0708995401.HKD","SG9999000418.SGD","SG9999015341.SGD","LU0256863811.USD","SG9999002224.SGD","SG9999014567.USD","LU0708994859.HKD","LU0787776722.HKD","LU1242518857.USD","LU1974910355.USD","BK4608","BK4548","LU2361044865.SGD","LU0225283273.USD","LU0345770993.USD","LU1934455863.HKD","LU2264538146.SGD","IE00BD6J9T35.USD","LU1633808545.USD","LU1923622291.USD","LU2552382215.SGD","LU1435385759.SGD","LU0320765059.SGD","SG9999014542.SGD","LU1988902786.USD","LU0689472784.USD","LU2244417387.USD","LU1699723380.USD","LU0724617625.USD","BK4534","IE0004445239.USD","LU1066051811.HKD","LU2491050071.SGD","LU2602419157.SGD","BK4141","IE00BQXX3D17.EUR","LU2087621335.USD","IE0004086264.USD","LU0048584097.USD","LU2326559502.SGD","LU2746668974.SGD","IE00BYXW3230.USD","LU2211815571.USD","LU1720051108.HKD","LU1037948541.HKD","LU0820561818.USD","LU0080751232.USD","LU2242650005.HKD","LU0345769631.USD","IE00BZ1G4Q59.USD","IE00BKPKM429.USD","LU1861220033.SGD","LU1791710400.SGD","LU0965508806.USD","LU1951198990.SGD","LU1868837136.USD","LU0310800379.SGD","LU1934455194.USD","LU2491049909.HKD","NVIW.SI","LU2065169927.USD","LU2860962120.EUR","LU0345770308.USD","LU0158827948.USD","LU2250418816.HKD","NVDY","LU1992135399.USD","BK4588","LU0069063385.USD","LU0079474960.USD","LU1116320737.USD","LU2452424414.USD","LU2286300806.USD","IE00B1XK9C88.USD","LU0265550946.USD","LU1084165304.USD","LU2462157665.USD","LU2360032135.SGD","LU2077746001.SGD","LU0466842654.USD","LU2461242641.AUD","LU1674673691.USD","LU0308772762.SGD","LU2471134523.USD","LU1551013425.SGD","SGXZ23171101.USD","LU2265009873.SGD","BK4567","LU2471134796.USD","LU0097036916.USD","LU1623119135.USD","LU0985320562.USD","LU1366333091.USD","LU1935043536.SGD","IE00BJTD4N35.SGD","LU0211328371.USD","LU0274383776.USD","LU0823414478.USD","LU1712237335.SGD","SG9999018865.SGD","IE00B4JS1V06.HKD","LU2168563687.JPY","LU1145028129.USD","LU2242649171.HKD","LU1066053197.SGD","LU0061475181.USD","SG9999015952.SGD","LU0029864427.USD","LU1069344957.HKD","LU1429558221.USD","LU2097344431.USD","LU1066051498.USD","LU1244550494.USD","LU1116320901.HKD","LU0942090050.USD","IE00BN29S564.USD","LU2023250330.USD","IE0001KFT4U8.USD","LU1935042215.USD","LU0072462426.USD","LU2272731782.SGD","LU0472753341.HKD","SG9999014914.USD","LU0316494557.USD","IE00BDCRKT87.USD","SG9999014575.USD","LU1267930573.SGD","IE00BKDWB100.SGD","LU1868836591.USD","IE00B19Z8X17.USD","LU2083900584.USD","LU0345768153.USD","LU1035775433.USD","LU1815336760.USD","LU2092937148.SGD","BK4503","LU2237957902.USD","3NVD.UK","LU2063271972.USD","LU2237957811.SGD","LU2471134879.HKD","LU2543165471.USD","SG9999015945.SGD","BK4532","LU0096362180.USD","LU0107464264.USD","LU1861215975.USD","LU2750360997.AUD","LU0965509101.SGD","LU1037948897.HKD","LU1629891620.HKD","LU2125909247.SGD","LU1821325948.USD","LU0198837287.USD","LU0689626769.HKD","LU1064131342.USD","LU2420271590.USD","LU0238689110.USD","LU0266013472.USD","LU1551013342.USD","NVD3.UK","LU0265550359.USD","IE00BHPRN162.USD","LU0154236417.USD","LU1868836757.USD","LU0640476718.USD","IE00BFSS7M15.SGD","IE00B775H168.HKD","LU2430703178.SGD","LU0170899867.USD","BK4550","LU2746668461.USD","LU2023250504.SGD","LU0823414551.USD","LU2433249047.HKD","LU0823421416.USD","LU1267930730.SGD","LU1923622614.USD","LU1803068979.SGD","LU2430703251.USD","LU0417517546.SGD","SG9999018857.SGD","IE00B3M56506.USD","LU1935043023.USD","LU0820562030.AUD","BK4527","SG9999015978.USD","IE00B19Z9505.USD","LU2168564065.EUR","LU0081259029.USD","LU1267930490.SGD","LU0353189763.USD","LU0882574139.USD","LU0957808578.USD","HK0000320264.USD","LU0642271901.SGD","LU0390134368.USD","LU1852331112.SGD","LU0210533765.USD","LU2087625088.SGD","GB00BDT5M118.USD","LU1323610961.USD","LU0823434740.USD","LU1935042991.SGD","LU2272731600.USD","LU2089284900.SGD","LU2357125470.USD","LU2089283258.USD","SGXZ99366536.SGD","LU0354030438.USD","LU0276348264.USD","2NVD.UK","LU0056508442.USD","IE00B19Z8W00.USD","LU1914381329.SGD","BK4605","LU0057025933.USD","LU2023251221.USD","LU1718418525.SGD","LU1778281490.HKD","LU0557290698.USD","LU2361045086.USD","LU2089985449.USD","IE00BK4W5L77.USD","LU1119994496.HKD","LU2750360641.GBP","LU0965509283.SGD","BK4592","LU0861579265.USD","LU0251132253.USD","LU0215105999.USD","LU0979878070.USD","LU2168564222.USD","LU2322448957.HKD","LU1642822529.SGD","IE00BJJMRY28.SGD","LU2896262040.SGD","LU2756315664.SGD","IE00BMPRXN33.USD","LU2168564495.EUR","LU0157215616.USD","LU0348723411.USD","LU2191332357.HKD","LU0868494617.USD","IE0004091025.USD","LU2290526834.HKD","LU0082616367.USD","BK4587","LU0672654240.SGD","IE0005OL40V9.USD","LU0347712357.USD","LU1720051017.SGD","LU0444973449.USD","LU1280957306.USD","IE00B7KXQ091.USD","LU2028103732.USD","LU1316542783.SGD","LU0061474705.USD","LU1983260115.SGD","LU2473716301.USD","IE00BJJMRX11.SGD","LU0683600562.USD","IE0034235188.USD","BK4581","BK4529","LU1496350502.SGD","LU1571399168.USD","BK4549","LU2236285917.USD","LU0096364046.USD","LU0957791311.USD","IE00BMPRXR70.SGD","LU0203202063.USD","SGXZ51526630.SGD","LU0109392836.USD","NVDS.UK","LU1496350171.SGD","LU1861127337.USD","LU0786609619.USD","LU2403377893.USD","LU2111349929.HKD","LU2505996681.GBP","LU1989764664.SGD","LU1814569148.SGD","IE00BMPRXQ63.HKD","LU1815333072.USD","LU0788109477.HKD","LU1992135472.HKD","LU0719512351.SGD","LU2505996509.AUD","LU2065170008.USD","LU2125909759.SGD","LU0323591593.USD","LU2381873111.SGD","SG9999001424.SGD","SGXZ81514606.USD","BK4612","LU2413666426.HKD","LU1923623000.USD","LU0310799852.SGD","LU0061474960.USD","SG9999015986.USD","LU0124676726.USD","LU2054465674.USD","LU0127658192.USD","LU0109391861.USD","LU1232071149.USD","LU1721428933.USD","LU2463028550.USD","LU2487616109.SGD","LU0211327993.USD","LU0494093205.USD","IE00BKVL7J92.USD","LU0868494708.USD","BK4543","LU0353189680.USD","LU1244550221.USD","LU2417539215.USD","IE00BJLML261.HKD","LU2430703095.HKD","NVDX","LU0175139822.USD","IE0009356076.USD","NVDS","LU2125909916.SGD","LU0203201768.USD","BK4585","LU2552382058.USD","LU2552382132.HKD","SG9999014880.SGD","SG9999014559.SGD","SG9999002232.USD","LU0267386448.USD","LU2506951792.HKD","LU1244550577.SGD","LU0289739343.SGD","LU2272731865.HKD","LU0234572021.USD","NVDA","HK0000306685.HKD","HK0000320223.HKD","LU0820561909.HKD"],"gpt_icon":0},{"id":"1109800441","title":"Hoth Therapeutics启动VA支持的研究，探讨新型GDNF减肥疗法针对肥胖和脂肪肝疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1109800441","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109800441?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:50","pubTimestamp":1761565811,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics启动VA支持的研究，探讨新型GDNF减肥疗法针对肥胖和脂肪肝疾病","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"gpt_icon":0},{"id":"1186024761","title":"Hoth Therapeutics获得FDA孤儿药资格并为Ht-Kit在罕见C-Kit驱动癌症中的强大临床前数据进行报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1186024761","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186024761?lang=zh_cn&edition=full","pubTime":"2025-10-21 20:24","pubTimestamp":1761049450,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics获得FDA孤儿药资格并为Ht-Kit在罕见C-Kit驱动癌症中的强大临床前数据进行报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"gpt_icon":0},{"id":"1112517513","title":"Hoth Therapeutics通过专利申请扩展Ht-001开发项目，针对药物过敏反应、放疗皮疹及Menin抑制剂皮肤毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1112517513","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112517513?lang=zh_cn&edition=full","pubTime":"2025-09-24 20:14","pubTimestamp":1758716060,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics通过提交专利申请扩大其Ht-001药物的开发范围，重点针对药物诱发的过敏反应、放射治疗引起的皮疹以及Menin抑制剂相关的皮肤毒性反应等适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"gpt_icon":0},{"id":"1190581881","title":"Hoth Therapeutics发布股东更新：Ht-001、Ht-Kit、扩大财务储备策略及VA肥胖项目推动公司达到历史最强地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1190581881","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190581881?lang=zh_cn&edition=full","pubTime":"2025-09-16 20:15","pubTimestamp":1758024924,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics发布股东更新：Ht-001、Ht-Kit、扩大财务储备策略及VA肥胖项目推动公司达到历史最强地位","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"gpt_icon":0},{"id":"1135272188","title":"Hoth Therapeutics向EMA提交HT-001治疗EGFR抑制剂引起皮肤毒性癌症患者的II期临床试验申请，取得重要欧洲监管里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1135272188","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135272188?lang=zh_cn&edition=full","pubTime":"2025-09-10 20:31","pubTimestamp":1757507487,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics向欧洲药品管理局(EMA)提交了HT-001治疗因EGFR抑制剂引起皮肤毒性的癌症患者II期临床试验申请，成功取得了重要的欧洲监管里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"gpt_icon":0},{"id":"2518222824","title":"Hoth Therapeutics, Inc.盘中异动 股价大跌5.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518222824?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:33","pubTimestamp":1741613630,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时33分，Hoth Therapeutics, Inc.股票出现异动，股价大幅下跌5.50%。截至发稿，该股报1.03美元/股，成交量24.2463万股，换手率1.84%，振幅3.67%。Hoth Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Biodexa Pharmaceuticals Plc涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2087.41%、410.08%、63.40%，振幅较大的相关个股有Akero Therapeutics, Inc.、Xencor, Inc.、Seer, Inc.，振幅分别为100.05%、99.13%、98.72%。Hoth Therapeutics, Inc.公司简介：Hoth Therapeutics Inc是一家处于发展阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213350a26a257f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213350a26a257f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","HOTH","BK4139"],"gpt_icon":0},{"id":"2517948865","title":"Hoth Therapeutics, Inc.盘中异动 早盘股价大跌5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517948865?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:32","pubTimestamp":1741185179,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时32分，Hoth Therapeutics, Inc.股票出现波动，股价快速跳水5.65%。截至发稿，该股报1.17美元/股，成交量62.9736万股，换手率4.79%，振幅8.06%。Hoth Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为355.98%、258.41%、187.27%，振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Invivyd, Inc.，振幅分别为23.90%、15.31%、13.32%。Hoth Therapeutics, Inc.公司简介：Hoth Therapeutics Inc是一家处于发展阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223300963adc99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223300963adc99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","HOTH","LENZ"],"gpt_icon":0},{"id":"2503913326","title":"Hoth Therapeutics, Inc.盘中异动 股价大涨5.24%报1.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503913326","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503913326?lang=zh_cn&edition=full","pubTime":"2025-01-16 22:34","pubTimestamp":1737038065,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日22时34分，Hoth Therapeutics, Inc.股票出现波动，股价急速拉升5.24%。截至发稿，该股报1.59美元/股，成交量10.5469万股，换手率1.53%，振幅3.31%。Hoth Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.07%。Hoth Therapeutics, Inc.公司简介：Hoth Therapeutics Inc是一家处于发展阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116223425a2246028&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116223425a2246028&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","HOTH","LENZ"],"gpt_icon":0},{"id":"2503403366","title":"Hoth Therapeutics, Inc.盘中异动 大幅上涨6.13%报1.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503403366","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503403366?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:32","pubTimestamp":1736951570,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时32分，Hoth Therapeutics, Inc.股票出现异动，股价急速拉升6.13%。截至发稿，该股报1.65美元/股，成交量18.6844万股，换手率2.71%，振幅3.23%。Hoth Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.77%。其相关个股中，Monte Rosa Therapeutics, Inc.、Exicure, Inc.、Generation Bio Co.涨幅较大，Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Oncolytics Biotech Inc.较为活跃，换手率分别为185.08%、56.29%、35.47%，振幅较大的相关个股有Onconetix, Inc.、Klotho Neurosciences, Inc.、Eterna Therapeutics Inc.，振幅分别为14.29%、12.00%、11.55%。Hoth Therapeutics, Inc.公司简介：Hoth Therapeutics Inc是一家处于发展阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223250a222fe4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223250a222fe4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","HOTH"],"gpt_icon":1},{"id":"2501780733","title":"D. Boral Capital：维持Hoth Therapeutics(HOTH.US)评级，由买入调整至买入评级, 目标价由5.00美元调整至5.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2501780733","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501780733?lang=zh_cn&edition=full","pubTime":"2025-01-08 01:22","pubTimestamp":1736270551,"startTime":"0","endTime":"0","summary":"D. Boral Capital：维持Hoth Therapeutics(HOTH.US)评级，由买入调整至买入评级, 目标价由5.00美元调整至5.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"e25acbe0e1db95d44199b84b75be99c7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/08012247234108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","HOTH"],"gpt_icon":0},{"id":"2501207774","title":"Hoth Therapeutics, Inc.股价飙升100.71% 市值涨1143.76万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501207774","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501207774?lang=zh_cn&edition=full","pubTime":"2025-01-07 22:31","pubTimestamp":1736260283,"startTime":"0","endTime":"0","summary":"北京时间2025年01月07日22时31分，Hoth Therapeutics, Inc.股票出现异动，股价急速拉升100.71%。截至发稿，该股报1.645美元/股，成交量4533.34万股，换手率656.64%，振幅4.88%。Hoth Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.22%。其相关个股中，Hoth Therapeutics, Inc.、Conduit Pharmaceuticals Inc.、Immuneering Corporation涨幅较大，Hoth Therapeutics, Inc.、Immuneering Corporation、Scisparc Ltd.较为活跃，换手率分别为658.28%、157.62%、93.77%，振幅较大的相关个股有Immuneering Corporation、Conduit Pharmaceuticals Inc.、Sagimet Biosciences Inc. - Series A，振幅分别为6.78%、6.78%、6.41%。Hoth Therapeutics, Inc.公司简介：Hoth Therapeutics Inc是一家处于发展阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107223123aba1decf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107223123aba1decf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HOTH","BK4007","LENZ"],"gpt_icon":0},{"id":"2486033227","title":"Hoth Therapeutics, Inc.盘中异动 早盘股价大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486033227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486033227?lang=zh_cn&edition=full","pubTime":"2024-11-25 22:49","pubTimestamp":1732546141,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日22时49分，Hoth Therapeutics, Inc.股票出现波动，股价急速下挫5.13%。Hoth Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.32%。其相关个股中，Scholar Rock Holding Corporation、Bridgebio Pharma, Inc.、Mural Oncology Plc涨幅较大，Cognition Therapeutics, Inc.、木薯科学、Citius Pharmaceuticals, Inc.较为活跃，换手率分别为93.17%、78.41%、48.33%，振幅较大的相关个股有180 Life Sciences Corp C/Wts 07/11/2025、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Citius Pharmaceuticals, Inc.，振幅分别为61.31%、34.34%、30.87%。Hoth Therapeutics, Inc.公司简介：Hoth Therapeutics Inc是一家处于发展阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125224901abde0376&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125224901abde0376&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","HOTH","BK4007","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hoththerapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.1484},{"period":"3month","weight":-0.1053},{"period":"6month","weight":-0.2331},{"period":"1year","weight":0.1138},{"period":"ytd","weight":0.0303}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Hoth Therapeutics, Inc.于2017年5月16日根据内华达州法律注册成立。该公司是一家处于发展阶段的生物制药公司，专注于为患有特应性皮炎（又称湿疹）等疾病的患者提供靶向治疗。该公司的主要资产是与Chelexa的分许可协议，根据该协议，Chelexa已授予使用其BioLexa平台的独家分许可，该平台是在辛辛那提大学开发的专有、专利、药物化合物平台。该许可证允许为人类的任何适应症开发该平台。该公司最初的重点将是通过应用外用乳膏来治疗湿疹。BioLexa平台以局部剂型将FDA批准的锌螯合剂与一种或多种批准的抗生素相结合，通过防止传染性生物膜的形成以及由此引发症状的汗管堵塞，解决未经检查的湿疹发作问题。该公司是第一个旨在防止症状引发突发而不是简单地在出现症状时进行治疗的候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.045454},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.09197},{"month":3,"riseRate":0.5,"avgChangeRate":-0.042723},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.104332},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.054377},{"month":6,"riseRate":0.428571,"avgChangeRate":0.131646},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.05884},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.030926},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.061813},{"month":10,"riseRate":0,"avgChangeRate":-0.17286},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.033966},{"month":12,"riseRate":0.571429,"avgChangeRate":0.193643}],"exchange":"NASDAQ","name":"Hoth Therapeutics","nameEN":"Hoth Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Hoth Therapeutics(HOTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Hoth Therapeutics(HOTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Hoth Therapeutics,HOTH,Hoth Therapeutics股票,Hoth Therapeutics股票老虎,Hoth Therapeutics股票老虎国际,Hoth Therapeutics行情,Hoth Therapeutics股票行情,Hoth Therapeutics股价,Hoth Therapeutics股市,Hoth Therapeutics股票价格,Hoth Therapeutics股票交易,Hoth Therapeutics股票购买,Hoth Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Hoth Therapeutics(HOTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Hoth Therapeutics(HOTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}